Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Prospective, open-label, dose-ranging, uncontrolled phase I study with PM01183 in combination
with irinotecan to determine the maximum tolerated dose (MTD) and the recommended dose (RD)
of PM01183 in combination with irinotecan in patients with selected advanced solid tumors.